Revenue and net profit surged 55% and 74% year-over-year, driven by strong growth in medical equipment and radio-pharmaceuticals. EBITDA margin improved to 23%, with recurring revenues up 71%. Expansion in robotics and AI solutions supports a positive outlook.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.